Sunday, January 06, 2019 1:35:52 PM
The impact of the short interest has more to do with the daily volume as a practical matter.
The impact of the volume of short shares moving into or out of the market is based on the ratio of the short vol to the daily vol.
Especially if there is the long hoped for short squeeze.
Contemplate this. The short position increases when the share price is at a peak. If you look at the short interest and the share price relationship it appears that the shorts are in between $12 and $6.
Based on a short position of 5.5 mil shares that equates to an estimated short position value of $30 to $50 million.
That suggests to me that the people with the responsibility of overseeing that amount of money also have access to a few million $ to protect that position. Given the low share price and relatively low volume, it should be easy to have a significant impact on the share price.
Is that "the cabal"? It doesn't have to be an organized conspiracy. All that is required is several different organizations with a common interest. They don't need to communicate with each other. All they need is a common goal of protecting their investment. Watching the share price and volume and acting in their own individual self interests will result in apparently coordinated activity.
That easily explains the odd behavior of the share price when good news is released. It will also indicate that achieving a short squeeze will be far more difficult than has been speculated.
It will take a MAJOR event to create a short squeeze that the short position holders can not over come with the application of more money.
The impact of the volume of short shares moving into or out of the market is based on the ratio of the short vol to the daily vol.
Especially if there is the long hoped for short squeeze.
Contemplate this. The short position increases when the share price is at a peak. If you look at the short interest and the share price relationship it appears that the shorts are in between $12 and $6.
Based on a short position of 5.5 mil shares that equates to an estimated short position value of $30 to $50 million.
That suggests to me that the people with the responsibility of overseeing that amount of money also have access to a few million $ to protect that position. Given the low share price and relatively low volume, it should be easy to have a significant impact on the share price.
Is that "the cabal"? It doesn't have to be an organized conspiracy. All that is required is several different organizations with a common interest. They don't need to communicate with each other. All they need is a common goal of protecting their investment. Watching the share price and volume and acting in their own individual self interests will result in apparently coordinated activity.
That easily explains the odd behavior of the share price when good news is released. It will also indicate that achieving a short squeeze will be far more difficult than has been speculated.
It will take a MAJOR event to create a short squeeze that the short position holders can not over come with the application of more money.
If investing was easy, everyone would be rich by now.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
